Bazedoxifene is a selective estrogen receptor modulator (SERM) used to treat osteoporosis in postmenopausal women. It functions by mimicking estrogen’s beneficial effects on bone density, thereby reducing fracture risk. Its therapeutic use is listed as anti-osteoporosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Conbriza, Viviant and bazedoxifenum. Its PubChem CID is 154257.
Bazedoxifene
| CAS No | 198481-32-2 |
|---|---|
| Molecular Formula | C30H34N2O3 |
| Molecular Weight | 470.6 g/mol |
| Synonyms | 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Bazedoxifene is a selective estrogen receptor modulator (SERM) used to treat osteoporosis in postmenopausal women. It functions by mimicking estrogen's beneficial effects on bone density, thereby reducing fracture risk.
The listed CAS number is 198481-32-2.
The listed molecular formula is C30H34N2O3.
The listed molecular weight is 470.6 g/mol.
1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol.
The source lists Conbriza, Viviant and bazedoxifenum.